Alnylam Reports Phase 1/2 Results For Its Drug Candidate ALN-CC5 By: TalkMarkets June 12, 2015 at 21:03 PM EDT Shares of Alnlyam ended the day down almost 2% after posting early phase 1/2 results for its drug candidate ALN-CC5. Read More >> Related Stocks: Alexion Pharmaceuticals Alnylam Pharmaceuticals Sanofi-Aventis S.A. ADR